Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Deborah J. Wexler MD, MSc Associate Editor

Kathleen M. Dungan MD, MPH Advisory Board

Silvio E. Inzucchi MD Editor-in-Chief

See All Experts

featured

Published in Diabetes

Journal Scan / Research · June 17, 2020

Lixisenatide Reduces Postprandial Glucose in Patients With Diabetes Secondary to Total Pancreatectomy

Diabetologia

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Michael Nauck MD

Diabetologia

The GLP-1 Receptor Agonist Lixisenatide Reduces Postprandial Glucose in Patients With Diabetes Secondary to Total Pancreatectomy: A Randomised, Placebo-Controlled, Double-Blinded Crossover Trial

Diabetologia 2020 Jul 01;63(7)1285-1298, CTB Juel, A Lund, MM Andersen, CP Hansen, JH Storkholm, JF Rehfeld, G van Hall, B Hartmann, NJ Wewer Albrechtsen, JJ Holst, T Vilsbøll, FK Knop

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Lixisenatide Reduces Postprandial Glucose in Patients With Diabetes Secondary to Total Pancreatectomy

Additional Info

The GLP-1 Receptor Agonist Lixisenatide Reduces Postprandial Glucose in Patients With Diabetes Secondary to Total Pancreatectomy: A Randomised, Placebo-Controlled, Double-Blinded Crossover Trial

Further Reading

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Effect of Long-Term Glycemic Burden on the Incidence of Diabetic Foot Ulcers

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Prognosis of Severe Hypoglycaemia and Diabetic Ketoacidosis in Adults Presenting to an Emergency Department

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Recently Updated